Evidence map›Paper›PMID 29523279›Full record

ArticlePregnancy hypertension2018

Pharmacokinetics of amlodipine besylate at delivery and during lactation.

Jamie L Morgan, Benjamin K Kogutt, Claudia Meek, Elizabeth K Stehel, Donald D McIntire, Jeanne S Sheffield, Scott W Roberts

Open access · greenAbstract read
In one paragraph

Article in Pregnancy hypertension, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Kidney disease and reproductive health.Nature reviews. Nephrology · 2025
    Review
  5. Review
  6. Glomerular Disease in Women.Kidney international reports · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jamie L MorganDepartment of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, United States. Electronic address: jamie.morgan@utsouthwestern.edu.
Benjamin K KoguttDepartment of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Claudia MeekClinical Pharmacology and Experimental Therapeutics Center, Texas Tech School of Pharmacy, Dallas, TX, United States.
Elizabeth K StehelDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Donald D McIntireDepartment of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
Jeanne S SheffieldDepartment of Obstetrics and Gynecolgy, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Scott W RobertsDepartment of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
The University of Texas Southwestern Medical Center · USJohns Hopkins University · USTexas Tech University · US

Funding

UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
NCATS NIH HHS UL1 TR001105
6 · The paper itself

Abstract

backgroundAmlodipine is rarely used in the treatment of pregnant hypertensive women due to limited pharmacokinetic data during pregnancy and the postpartum period.

objectiveTo evaluate the pharmacokinetics of amlodipine besylate in the peri-partum period including quantities of placental passage, breast milk excretion and infant exposure. STUDY

designThis was a prospective study of pregnant women who were prescribed 5 mg of amlodipine daily for treatment of chronic hypertension and delivered at term. Cord and maternal blood samples were collected at delivery. On postpartum day 2, six paired maternal plasma and breast milk samples were obtained at 4, 6, 8, 12, 15 and 24 h following amlodipine dosing. Infant plasma samples were collected 24-48 h after delivery. All samples were analyzed for amlodipine concentration. A one compartment, first-order model was used to calculate pharmacokinetic estimates for maternal plasma.

resultsOf the 16 patients enrolled in the study, 11 had cord blood and maternal serum collected at delivery, of which only 6 produced sufficient breast milk for sampling. Amlodipine was detected in infant cord blood plasma with a mean concentration of 0.49 ± 0.29 ng/mL compared to mean maternal serum level of 1.27 ± 0.84 ng/mL. Amlodipine concentrations in both in breast milk and infant plasma were undetectable at the lower limit of assay detection (<0.1 ng/mL). In the immediate postpartum period, the amlodipine elimination half-life was 13.7 ± 4.9 h, the area under the curve was 53.4 ± 19.8 ng*h/mL and the peak concentration was 2.0 ± 1.0 ng/mL.

conclusionsAmlodipine does cross the placenta in measurable quantities, but is not detected in breast milk or infant plasma at 24-48 h of life indicating that it is likely safe to use during the peripartum period.

Indexed as

Delivery, ObstetricAdultAmlodipineAntihypertensive AgentsChronic DiseaseDrug MonitoringFemaleFetal BloodHumansHypertension, Pregnancy-InducedInfant, NewbornLactationMaternal-Fetal ExchangeMilk, HumanModels, BiologicalPregnancyAmlodipineAntihypertensive AgentsAmlodipineBreast milkChronic hypertensionPharmacokinetics

Identifiers

PMID29523279
PMCPMC5846630
OpenAlexW2781596597

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.